Compare Novo Nordisk A/S (NVO) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs NEOS S&P 500 High Income ETF — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while NEOS S&P 500 High Income ETF trades at $54.09 (market cap $12.50B). The key difference: Novo Nordisk A/S is far larger — about 13.2× NEOS S&P 500 High Income ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while NEOS S&P 500 High Income ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and NEOS S&P 500 High Income ETF for 58 Days on average.
| NVO | SPYI | |
|---|---|---|
Market Cap | $165.31B | $12.50B |
Volume | 11,432,838 | 3,058,962 |
Sector | Health | Income / Options Overlay |
52-Week High | $63.98 | $54.42 |
52-Week Low | $35.29 | $47.98 |
Typical Hold Time | 116 Days | 58 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
SPYI trades at $53.86, down 0.28% with a bullish technical signal from moving averages but neutral oscillators. The ETF shows strong income focus with recent monthly dividends around $0.53-0.54, though financial ratios remain undisclosed. Recent news highlights SPYI's popularity for high-yield strategies while raising concerns about principal erosion from covered call strategies.
Outlook remains mixed with technical strength offset by fundamental questions about long-term capital preservation. The ETF appeals to income-seeking investors but faces sequence risk in retirement portfolios. Key risks include covered call limitations during bull markets and sensitivity to market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
